Meridian Bioscience Q3 Revenues Rise 18 Percent Aided by MDx Business

The company will be submitting an application this week to the US Food and Drug Administration for its second molecular test, the illumigene GBS test for Group B streptococcus.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories